69f73cc3_anderbilt_Ingram_Cancer_Center__Trial_Type
[Protocol No. & Open Date] VICCMD1403 06/02/2014 [Summary] An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification [Trial Type] 
Treatment Bladder Colon Esophageal Gastric/Gastroesophageal Neuro-Oncology Ovarian Urologic Uterine
Urologic / Genitourinary Cancers - Vanderbilt-Ingram Cancer Center
Trial Type